North America Genotyping Market Forecast to 2031 - Regional Analysis - by Product Type, Technology, Application, and End user

List of Tables

The North America genotyping market was valued at US$ 12,044.57 million in 2023 and is expected to reach US$ 62,900.63 million by 2031; it is estimated to record a CAGR of 23.0% from 2023 to 2031.

Use in Diagnosis of Genetic and Rare Diseases Fuels North America Genotyping Market

According to the World Health Organization (WHO), ~35 million new cancer cases are likely to occur in 2050, a 77% increase from the corresponding 20 million cases in 2022. In 2022, the Alzheimer's Association stated that the number of people living with Alzheimer's in the US is rapidly increasing. The disease affects more than 6 million Americans from all age groups. As per the association's estimates, 6.5 million Americans aged more than 65 suffered from Alzheimer's as of 2022, and 73% of this population was aged 75 or older. As per a study published in the Journal of Health Monitoring, up to 300 million people worldwide suffer from rare diseases. Although individual diseases are rare, they collectively pose significant challenges to the global healthcare system.

Since cancer, Alzheimer's disease, and rare diseases are difficult to identify clinically, genotyping stands as the backbone of diagnostic testing in the population. DNA sequences obtained from genotyping can be compared to sample or reference sequences to determine variations. Genotyping is also employed to detect single-nucleotide polymorphisms (SNPs), which are minor variations in genetic complement within the population. The human genome has nearly 660 million SNPs, which makes them the most widespread genetic variation. Moreover, by comparing polymorphisms in healthy and diseased populations, genome-wide association studies (GWAS) can uncover links between common illnesses and SNPs. GWAS can untangle the molecular mechanisms in underlying disease states by finding probable causes. SNPs are even present in single-celled organisms, such as bacteria. SNP genotyping can discriminate between microorganism isolates and could even be accustomed to identifying antibiotic-resistant strains. SNP-based strain detection has a significant impact on each pharmaceutical and clinical analysis, and it has also been used in infectious disease epidemiology.

North America Genotyping Market Overview

The North America genotyping market is segmented into the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging research and development activities are the factors benefiting the genotyping market in this region. Moreover, government-led programs such as the "All of Us Research Program," initiatives by various genomic communities, and the increasing awareness of genotyping services are the key drivers of the market expansion across North America.

North America Genotyping Market Revenue and Forecast to 2031 (US$ Million)

North America Genotyping Market Segmentation

The North America genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the North America genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the North America genotyping market is categorized into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the North America genotyping market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the North America genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the North America genotyping market is segmented into the US, Canada, and Mexico. The US dominated the North America genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments, Inc, TRIMGEN CORPORATION, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the North America genotyping market.

Product Code: BMIRE00025971

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. North America Genotyping Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Global Market Share Analysis
- 4.3.1 Global Market Share (%) of Leading Players for NGS Library Preparation
- 4.3.2 Global Market Share (%) of Leading Player for Genotyping
- 4.3.3 Global Market Share (%) of Leading Player for Gene Expression

5. North America Genotyping Market - Key Market Dynamics

5.1 Market Drivers:
- 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
- 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
5.2 Market Restraints
- 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
5.3 Market Opportunities
- 5.3.1 Expanding Range of Applications
5.4 Future Trends
- 5.4.1 Increasing Popularity of Personalized Medicine
5.5 Impact of Drivers and Restraints:

6. Genotyping Market - North America Analysis

6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. North America Genotyping Market Analysis - by Product Type

7.1 Instruments
- 7.1.1 Overview
- 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Reagents and Kits
- 7.2.1 Overview
- 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Bioinformatics
- 7.3.1 Overview
- 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Genotyping Services
- 7.4.1 Overview
- 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Genotyping Market Analysis - by Technology

8.1 Microarray
- 8.1.1 Overview
- 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Capillary Electrophoresis
- 8.2.1 Overview
- 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Sequencing
- 8.3.1 Overview
- 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Polymerase Chain Reaction (PCR)
- 8.4.1 Overview
- 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
- 8.5.1 Overview
- 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Other Technologies
- 8.6.1 Overview
- 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Genotyping Market Analysis - by Application

9.1 Pharmacogenomics
- 9.1.1 Overview
- 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Diagnostics and Personalized Medicine
- 9.2.1 Overview
- 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Animal Genetics
- 9.3.1 Overview
- 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Agricultural Biotechnology
- 9.4.1 Overview
- 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Other Applications
- 9.5.1 Overview
- 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Genotyping Market Analysis - by End-user

10.1 Pharmaceutical and Biopharmaceutical Companies
- 10.1.1 Overview
- 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Diagnostic and Research Laboratories
- 10.2.1 Overview
- 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Academic Institutes
- 10.3.1 Overview
- 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Other End Users
- 10.4.1 Overview
- 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Genotyping Market - Country Analysis

11.1 North America
- 11.1.1 North America: Genotyping Market - Revenue and Forecast Analysis - by Country
  - 11.1.1.1 United States: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.1.1 United States: Genotyping Market Breakdown, by Product Type
    - 11.1.1.1.2 United States: Genotyping Market Breakdown, by Technology
    - 11.1.1.1.3 United States: Genotyping Market Breakdown, by Application
    - 11.1.1.1.4 United States: Genotyping Market Breakdown, by End-user
  - 11.1.1.2 Canada: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.2.1 Canada: Genotyping Market Breakdown, by Product Type
    - 11.1.1.2.2 Canada: Genotyping Market Breakdown, by Technology
    - 11.1.1.2.3 Canada: Genotyping Market Breakdown, by Application
    - 11.1.1.2.4 Canada: Genotyping Market Breakdown, by End-user
  - 11.1.1.3 Mexico: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.3.1 Mexico: Genotyping Market Breakdown, by Product Type
    - 11.1.1.3.2 Mexico: Genotyping Market Breakdown, by Technology
    - 11.1.1.3.3 Mexico: Genotyping Market Breakdown, by Application
    - 11.1.1.3.4 Mexico: Genotyping Market Breakdown, by End-user

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in Genotyping Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 QIAGEN NV
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Merck KGaA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Thermo Fisher Scientific Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 BioTek Instruments, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 TRIMGEN CORPORATION
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Illumina Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Danaher Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Bio-Rad Laboratories Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 GE HealthCare Technologies Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Standard BioTools Inc
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 Laboratory Corp of America Holdings
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments
13.13 Beckman Coulter Inc
- 13.13.1 Key Facts
- 13.13.2 Business Description
- 13.13.3 Products and Services
- 13.13.4 Financial Overview
- 13.13.5 SWOT Analysis
- 13.13.6 Key Developments
13.14 BGI
- 13.14.1 Key Facts
- 13.14.2 Business Description
- 13.14.3 Products and Services
- 13.14.4 Financial Overview
- 13.14.5 SWOT Analysis
- 13.14.6 Key Developments
13.15 Takara Bio Inc
- 13.15.1 Key Facts
- 13.15.2 Business Description
- 13.15.3 Products and Services
- 13.15.4 Financial Overview
- 13.15.5 SWOT Analysis
- 13.15.6 Key Developments
13.16 DiaSorin SpA
- 13.16.1 Key Facts
- 13.16.2 Business Description
- 13.16.3 Products and Services
- 13.16.4 Financial Overview
- 13.16.5 SWOT Analysis
- 13.16.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms